Chronic pain is an important public health problem that negatively impacts quality of life of affected individuals and exacts an enormous socio-economic cost. Currently available therapeutics provide inadequate management of pain in many patients. Acute pain states generally resolve in most patients. However, for reasons that are poorly understood, in some individuals, acute pain can transform to a chronic state. Our understanding of the risk factors that underlie the development of chronic pain is limited. Recent studies have suggested an important contribution of dysfunction in descending pain modulatory circuits to pain 'chronification'. Human studies provide insights into possible endogenous and exogenous factors that may promote the conversion of pain into a chronic condition.
INTRODUCTION
There is little argument that chronic pain represents an urgent medical need worldwide [1] . Chronic pain is consistently reported as one of the most frequent complaints driving patients to seek medical attention [2] . It exerts a high socio-economic cost, estimated to be between US$560 and US$635 billion annually in terms of healthcare costs and lost productivity [3] . The reported prevalence of chronic pain varies widely. In the USA, estimates of chronic pain prevalence ranged from a low of 15 [4] to a high of 64% [5] , a range likely resulting from differences in data collection methods. Similarly, wide ranges in chronic pain prevalence were found when surveys were performed globally (from 2 to 55%) or in Europe (from 5 to 33%) [2] . In a recent internet-based study performed in the USA, 9326 respondents indicated chronic pain satisfying the International Association for the Study of Pain definition [2] . Of these, twothirds had medically diagnosed conditions, with low back pain, osteoarthritis, rheumatoid arthritis and migraine headache accounting for 18, 16, 6 and 3%, respectively, of the total prevalence [2] . In spite of its prevalence, chronic pain is inadequately managed with treatment success rates of only about 30% [6] .
THE VARIABILITY OF CHRONIC PAIN
The large variability among published reports of the prevalence of chronic pain suggests that there is considerable fluidity in the manifestation of this condition. Indeed, this argument is strengthened when one considers the profound differences in vulnerability of individuals to develop chronic pain after injury, disease or surgery [7 && ]. Of patients with diabetic neuropathy, only one-third developed painful diabetic neuropathy [8] . In a study of 15 692 diabetic patients in England, 26% of patients without neuropathy reported pain as did 60% of those with severe neuropathy [8] . In that study, it was found that incidence of pain increased with age, and that women had a 50% greater chance of developing chronic pain than did men. Approximately one-third of patients with low back pain develop persistent pain that lasts over 1 year [9] . The risk of developing chronic pain after surgery, or persistent postsurgical pain (PPP), ranges from 5 to 50% of surgical patients, and between 2 and 10% of these develop severe pain [7 && ,10-12]. Although hernia repair and Caesarian section are associated with a 10% incidence of PPP, the risk of PPP after mastectomy, thoracotomy or amputation is 30, 40 and 50%, respectively [7 && ]. It appears that the likelihood of developing chronic PPP is related more to the intensity of the acute pain felt immediately postoperatively, rather than to the procedure itself [12] . No correlation has been identified between the degree of joint damage and intensity of pain in patients with osteoarthritis [7 && ]. Complex regional pain syndrome (CRPS) is a disabling chronic pain condition, yet it may be provoked by injury as apparently trivial as venipuncture [13, 14] , by other neurologic insults or by postherpetic neuralgia (PHN) and by mild or nonapparent zoster (i.e. sine herpete) [15] . In a recent review of CRPS, about onehalf of patients who developed PHN of the arms or legs eventually showed signs of CRPS, whereas none who had PHN of the head or neck did so [15] . It was concluded that CRPS represents an 'endophenotype' arising from even minor injury in susceptible individuals [15] .
The mechanisms that drive the development of chronic pain and the potential risk factors that may predispose an individual to a chronic pain state are largely unknown. Andersen and Kehlet [16] found that radiotherapy and nerve damage were risk factors for postmastectomy persistent pain, but inconsistencies among studies prevented the identification of other clear risk factors. It was suggested that future studies include factors such as age, weight, ethnicity and socioeconomic status, as well as preoperative pain, nociceptive function and psychosocial factors [16] . A more recent investigation by the same team found that demographic factors, surgical methods and treatment-related variables were less important in the development of postmastectomy persistent pain than psychosocial variables such as catastrophizing, somatization, sleep, anxiety and depression [17 & ]. In a prospective study of patients undergoing breast cancer surgery, Sipila
KEY POINTS
Multiple regions of the brain have been shown to be associated with nociceptor activation. These regions overlap with those that process emotion and motivation and that likely mediate the affective (aversive) aspects of pain.
Human and animal studies employing pharmacologic and neurochemical means have identified bidirectional pain modulatory systems arising from pontomedullary sites. These regions engage descending noradrenergic and serotonergic systems that can enhance or attenuate nociceptive inputs at the spinal level. Emerging evidence indicates that circuits involved in emotional learning can influence the activity of these descending pain modulatory systems.
Recent studies suggest that patients with established chronic pain tend to demonstrate an attenuated endogenous pain inhibitory process when compared with pain-free individuals. Engagement of descending inhibition may represent an endogenous mechanism that protects against pain chronification. Patients with dysfunctional pain (pain in the absence of apparent injury) show an apparent loss of descending inhibition (i.e. conditioned pain modulation, DNIC).
Apparent loss of descending inhibition may reflect enhanced descending facilitation or both. Drugs effective in the treatment of chronic pain often act by mimicking the actions of endogenous descending inhibition suggesting that new pharmacological treatments may be discovered by understanding the specifics of descending pain modulatory circuits. ]. Although increased age is associated with an increased risk of PHN, young age is a risk factor for PPP [7 && ,10,11]. It is generally agreed that the risks of developing chronic pain include genetic predispositions and prior exposures to injury, as well as psychosocial factors that are less readily identified such as catastrophizing, social support, economic status, pain expectation and past experiences [7 && ,10,11]. Recent advances in neuroimaging techniques and computational analysis have enabled investigators to noninvasively evaluate the brain function in individuals and patients increasing our understanding of the circuits underlying perception of pain. Numerous imaging studies have indicated that noxious stimuli activate several key brain regions, including cortical sites and limbic structures associated with emotional processing [20] [21] [22] . Moreover, neuroimaging studies have also shown that chronic pain may be accompanied by alterations in structural features, functional connectivity or activity of these sites [23] [24] [25] [26] . Although these brain regions are generally associated with emotional systems, they also interact with structures that encode descending pain modulation [7 && ]. Activation of nociceptors by stimuli that can potentially elicit tissue damage engages broad neural networks in the brain that reflect the meaningful experience of pain from sensory input. In addition to its sensory components, pain is also associated with a powerful affective component [27 & ,28,29] . Given the emotional or affective contributions to the pain experience, it is not surprising that chronic pain patients suffer from psychological and sociologic complications that are a further burden in addition to the already existing pain [30, 31] . As pain progresses from an acute origin, as from an injury or surgery, to a chronic condition, the negative emotional states associated with chronic pain not only exacerbate physiological pain sensitivity [32 && ] but also increase the incidence of comorbidities such as depression, anxiety, sleep disturbance, decision-making abnormalities and can even increase the risk for suicide [33,34 & ]. In spite of its prevalence and impact on patients' lives and on society, chronic pain is still poorly managed and current therapies provide inadequate relief [35, 36] . Therefore, increased understanding of mechanisms that may drive chronic pain, including those that address the affective aspects of pain, are key factors in the development of new therapies for clinical management of chronic pain.
PAIN PROCESSING IN BRAIN
The advances in neuroimaging techniques seen within the past 2 decades have led to a virtual explosion in the numbers of studies on the human brain's activity under conditions of acute pain and chronic pain. These noninvasive techniques have provided corroborative evidence that brain regions found to contribute to pain processing and modulation by pharmacologic or electrophysiologic means in animal studies correspond to regions of the human brain that are responsive to pain. In addition, these investigations have also shown that pain activates a network of brain regions affecting somatosensory and emotional aspects.
Sites activated by noxious stimulation
Neuroimaging studies have led to the identification of brain regions activated by noxious stimuli, including the primary somatosensory cortex (S1), secondary somatosensory cortex (S2), anterior cingulate cortex (ACC), prefrontal cortex (PFC), insula, amygdala, thalamus, cerebellum and the mesolimbic reward circuit, which includes the ventral tegmental area (VTA) and nucleus accumbens (NAc) [20,37,38 & ]. The somatosensory cortices (S1 and S2) and the insula are believed to encode the sensory features of pain, which include quality (stinging, burning or aching), location and duration [37,38 & ,39]. The prefrontal region and the limbic system (ACC, PFC, amygdala, VTA and NAc) encode emotional and motivational responses, and are implicated in the affective and contextual aspect of pain [37,38 & ,39] . It is important to emphasize that these regions are not selectively or exclusively activated by nociception or restricted solely to pain perception. Rather, regions serving several neurological functions including cognition, emotion, motivation and sensation are functionally connected in the context of nociception and give rise to the experience of pain [39, 40] . The interactions among these sites also provide a means whereby emotional and motivational cues can alter the experience and perception of pain through interactions with the descending pain modulatory system [7 && ,41].
DESCENDING PAIN MODULATION
Numerous investigations over the past half-century have established that activation of midbrain and medullary sites can exert bidirectional control over nociception. The periaqueductal gray (PAG) receives inputs from higher brain centers and is capable of activating a powerful analgesic effect. The rostroventromedial medulla (RVM) can both facilitate or inhibit nociceptive inputs and acts as a final relay in the control of descending pain facilitation. These structures provide a mechanism through which cortical and subcortical sites can influence nociception.
Periaqueductal gray and rostroventromedial medulla
The periaqueductal gray (PAG) is the first brain region to have been explicitly demonstrated to activate an endogenous pain inhibitory system. Early studies showed that microinjection of opioids or electrical stimulation applied into this region elicited a powerful antinociceptive effect in animals [42, 43] and humans [44] [45] [46] . Analgesia produced by PAG stimulation or microinjection of opioids is naloxone-reversible [44, [47] [48] [49] [50] . It is now well established that the PAG is a source of descending opioid-mediated inhibition of nociceptive inputs [47, 51, 52] . This region receives inputs from cortical sites and has reciprocal connections with the amygdala [53, 54] as well as ascending nociceptive inputs from the spinal dorsal horns by way of the parabrachial nuclei [54] . Imaging studies in human volunteers showed that the rostral ACC (rACC) likely mediates expectation and placebo analgesia by activation of the PAG [55, 56] . The PAG influences descending pain modulation primarily through its reciprocal connections with the rostroventromedial medulla (RVM) [57] . For example, excitation of PAG neurons also excites the activity of RVM neurons and is associated with inhibition of nocifensive reflexes in the rat [58] . The PAG is therefore well localized to modulate nociceptive inputs and pain perception through its interactions with ascending and descending projections from numerous sites.
The RVM includes the serotonergic nucleus raphe magnus (NRM), the nucleus reticularis gigantocellularis-pars alpha and the nucleus paragigantocellularis lateralis [57, 59] . In addition to the PAG, the RVM also receives inputs from the thalamus, the parabrachial region and the noradrenergic locus coeruleus, and is considered to be the final common relay in descending modulation of pain, projecting to the spinal dorsal horns as well as the trigeminal nucleus caudalis [57, 59, 60] . The RVM exerts a bidirectional pain modulatory effect, both inhibiting and facilitating pain. Early studies identified 'oncells' that increased their activity in response to noxious stimuli and prior to a nociceptive reflex, whereas 'off-cells' ceased firing immediately prior to the tail-flick [57, 59, 60] . Moreover, opioids inhibit on-cells and cause excitation of off-cells, and the latter effect is considered 'necessary and sufficient' to produce analgesia [57, 60] . The existence of oncells and off-cells with descending projections to the spinal dorsal horns provides a neuronal context for positive and negative pain modulation from the PAG/RVM system [60] . Moreover, as this system receives inputs from higher cortical sites, it also provides a mechanism whereby homeostatic or existential priorities may tone down or augment nociceptive inputs [60] . Finally, it is also suggested that an imbalance between the inhibitory and facilitatory descending pain modulatory systems may underlie pathological pain states [7 && ,10,17 & ,60]. Numerous studies performed in animal models of neuropathic or inflammatory pain support this view. Injury or inflammation enhance RVM on-cell activity, and pharmacological, neurochemical or physical disruption of descending facilitation from the RVM has abolished enhanced behavioural responses to evoked stimuli without attenuating acute, protective nociceptive reflexes [61] [62] [63] [64] [65] [66] [67] . More recently, inhibition of the RVM by microinjection of local anaesthetics reversed ongoing pain in models of neuropathic pain and of migraine [68,69 & ]. Importantly, a recent imaging study with humans showed that activation of this region is specifically related to development and maintenance of central sensitization [70] .
Spinal serotonergic activity modulates pain
The RVM includes major serotonergic nuclei, the NRM and the NpGC, as well as GABAergic and glycinergic neuronal populations, all of which have descending projections to the spinal cord [71] [72] [73] [74] [75] [76] . However, there is conflicting evidence regarding the nature of on-cells and off-cells viz-a-viz neurotransmitter content, and whether these neurons are indeed serotonergic, nonserotonergic or represent mixed populations [71] [72] [73] [74] [75] [76] . Sufficient evidence exists to indicate that activation of descending projections from the RVM elicits release of serotonin in the spinal dorsal horns, either from terminals of direct projections or from spinal interneurons [71] [72] [73] [74] [75] [76] . However, spinal 5-hydroxytryptamine (5-HT) can be pronociceptive or antinociceptive, depending on the 5-HT receptor subtype activated. Thus, activation of the 5-HT 1A , 5-HT 1B , 5-HT 1D and 5-HT 7 receptors tends to be antinociceptive, whereas the 5-HT 2A and 5-HT 3 receptor tend to promote nociception [77] [78] [79] [80] [81] [82] . Antinociception in mice produced by RVM morphine was blocked by spinal 5-HT 7 antagonist and hyperalgesia produced by RVM CCK was blocked by a spinal 5-HT 3 antagonist [78] . In other studies in mice, systemic 5-HT 7 agonists blocked hyperalgesia, whereas 5-HT 7 antagonists elicited enhanced pain [83] . Taken together, these observations indicate an important serotonergic role for bidirectional pain modulation.
Descending noradrenergic pain modulation
Descending noradrenergic projections to the spinal dorsal horns arise from the A5, the locus coeruleus (A6) and the Kölliker-Füse (A7) pontine noradrenergic nuclei, and these regions communicate with the RVM and PAG [84] [85] [86] [87] . Thus, these noradrenergic projections form an important component of descending pain modulation. Numerous animal studies showed that chemical or electrical stimulation of the noradrenergic nuclei, as well as the PAG or RVM, released norepinephrine into spinal cerebrospinal fluid and produced antinociception that was blocked by spinal a2-adrenergic receptor antagonists [87] . Activation of spinal a 2 -adrenergic receptors can inhibit nociceptive transmission both presynaptically and postsynapticically [87, 88] . Spinally administered a 2 adrenergic agonists produce a strong antinociceptive effect [87, 89, 90] , and show a strong antinociceptive synergy with opioids [87, [89] [90] [91] . In contrast to the spinal a 2 -adrenergic receptors, activation of spinal a 1 -adrenergic receptors shows a pain facilitatory effect [92] . Spinal administration of a 2 -adrenergic agonists produce analgesia in humans as well [93, 94] .
Recent studies suggest that the activity of the descending noradrenergic system is augmented in conditions of nerve injury in an effort to compensate for enhanced nociceptive inputs [95] . Injury is associated with increased synthesis and release of norepinephrine along with an enhanced efficacy of spinal a 2 -adrenergic receptors [95] . Enhanced efficiency of this system was found to underlie the increased efficacy of spinal clonidine against behavioral signs of neuropathic pain in animal models [96, 97] . Enhanced spinal noradrenergic efficiency in injury or inflammation also provides a mechanistic basis for the clinical success of the serotonin/norepinephrine reuptake inhibitors (SNRIs) duloxetine and milnacipran in diabetic neuropathy, fibromyalgia and osteoarthritis [98] [99] [100] . Tapentadol and tramadol are analgesics with multifunctional mechanisms involving differing degrees of agonist activity at the m-opiate receptor and inhibition of norepinephrine reuptake [101 && ]. This dual action is believed to result in an a 2 -adrenergic/opiate synergy accounting for the success of these drugs in chronic pain [101 && ].
DYSREGULATION OF DESCENDING PAIN MODULATION MAY PROMOTE AND MAINTAIN CHRONIC PAIN
It is believed that descending pain facilitatory and inhibitory systems function in concert, thus maintaining a baseline state of sensory processing [59, 102] . Illness, injury or inflammation can perturb this balance, and if facilitation is favoured, enhanced pain is manifest, whereas an increase in inhibition can mask an underlying enhanced pain state, in effect maintaining a homeostatic state [59, 102, 103] . Xu et al. [104] had found that about 30% of Sprague-Dawley rats did not develop behavioural signs of neuropathic pain (i.e. tactile and cold allodynia) after spinal nerve ligation (SNL). The systemic or spinal administration of the a 2 -adrenergic receptor antagonist atipamezole, but not of naloxone, to these animals resulted in expression of tactile and cold allodynia. Importantly, the responses of rats that did show these signs initially were not exacerbated by atipamezole [104] . It was suggested that a tonic endogenous noradrenergic inhibitory control prevented expression of signs of enhanced pain so that lifting of the inhibition unmasked the enhanced pain state [104] . A recent study [105] evaluated the consequences of SNL surgery on behavioural signs of neuropathic pain in Holtzman rats; SNL produced allodynia in approximately one-half of these injured rats. In rats demonstrating allodynia due to nerve injury, blockade of RVM activity with lidocaine reversed both evoked hypersensitivity and produced conditioned place preference (CPP) revealing the presence of ongoing pain. Remarkably, in SNL rats that were not demonstrating evoked hypersensitivity (i.e. presumably 'pain-free'), RVM lidocaine precipitated allodynia and produced conditioned place aversion (CPA) [105] . Moreover, selective inhibition of pain inhibitory neurons of the RVM with the k-opioid agonist U69593 or spinal administration of the a 2 -adrenergic antagonist yohimbine also unmasked signs of enhanced pain in asymptomatic nerveinjured rats [105] . Electrophysiologic studies suggested that these 'pain-free' injured rats had a reduced functioning of RVM on-cells and enhanced function of RVM off-cells [105] . These results suggest that engagement of descending inhibition can protect against development of experimental neuropathic pain following injury, and that enhanced pain appears when descending inhibition is attenuated [105] . Most recently, studies performed with tibial nerve transection in rats found that descending noradrenergic inhibition delays the expression and extent of enhanced pain [106 && ]. Blockade of spinal a 2 -adrenergic receptors hastened the onset of behavioural sensitization as well as the onset of contralateral allodynia and enhanced Fos expression in the spinal dorsal horn [106 && ]. Collectively, these studies indicate that an intact and effective descending noradrenergic pain inhibitory system protects against the development of enhanced abnormal pain and that an imbalance between pain inhibition and facilitation can lead to enhanced abnormal pain.
The clinical implications of these observations are that individuals with dysfunction or attenuation of endogenous pain inhibition may be more likely to develop chronic pain. One example is that individuals with pancreatic cancer normally report pain only after the cancer has advanced to a late stage, most likely because the disease progression overwhelms descending inhibition [107] . A similar delay in enhanced pain responses is seen in a mouse model of pancreatic cancer, in which systemic naloxone administration unmasks pain when administered at early stages [107] . Several studies with humans support the concept that dysfunctional pain states or chronic pain may be due to a deficit in endogenous descending pain inhibitory systems, manifested as a loss of conditioned pain modulation (CPM) [ 117, 118] . In animals, loss of diffuse noxious inhibitory controls (DNICs) has been demonstrated with electrophysiologic studies in rats in which application of a noxious stimulus reduced or abolished an initial nociceptive response [119] . Additional studies showed that DNIC is integrated at the level of the dorsal reticular nucleus (DRt), which communicates with the PAG and RVM and projects to the spinal cord [120, 121] . Loss of DNIC was produced by persistent morphine exposure in rats, resulting in increased sensitivity to sensory stimuli of trigeminal neurons sensitive to dural stimulation [122] . Importantly, DNIC was restored in these animals by inactivating the RVM with lidocaine [122] . This study suggests that enhanced descending facilitation may appear as a loss of inhibition. Consequently, it is not clear which of these alterations in pain modulation are more important clinically.
CONCLUSION
Significant advances have been made in our understanding of endogenous mechanisms that detect and interpret acute, nociceptive pain. In contrast, the processes that lead to the development of chronic pain conditions remain obscure and incompletely understood. The need for advancement in this aspect of pain research is clear, as chronic pain remains a critical unmet clinical need. Imaging studies have begun to reveal those brain regions that may undergo neuroplastic changes leading to chronic pain, as have studies on functional connectivity. Baliki et al. [24] have demonstrated that the strength of the functional connectivity between the medial PFC and NAc predicts patients who will develop chronic low back pain with greater than 80% accuracy. Understanding of interaction between higher brain sites, such as those related to emotional learning with descending pain modulatory systems, is likely to reveal significant insights into mechanisms of chronification. Data support the apparent loss of net descending inhibition as a mechanism that promotes chronic pain while engagement of inhibition protects against chronic pain. Why different individuals may fail to engage descending protective mechanisms is not understood and requires further investigation. Understanding the role of descending modulatory circuits in pain chronification may lead to the discovery of new therapeutics.
